Aurora Cannabis Inc. (ACB) FinancialsACBAurora Cannabis Inc.

Aurora Cannabis Inc. (ACB) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Cannabis, accounting for 87.2% of total sales, equivalent to CAD 78.81M. Another important revenue stream is Plant propagation. Understanding this composition is critical for investors evaluating how ACB navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Aurora Cannabis Inc. maintains a gross margin of -5.95%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -67.86%, while the net margin is -5.97%. These profitability ratios, combined with a Return on Equity (ROE) of -7.09%, provide a clear picture of how effectively ACB converts its operational activities into shareholder value.

In the context of the broader market, ACB competes directly with industry leaders such as VITL and AFRI. With a market capitalization of $282.36M, it holds a significant position in the sector. When comparing efficiency, ACB's gross margin of -5.95% stands against VITL's 6.58% and AFRI's 10.42%. Such benchmarking helps identify whether Aurora Cannabis Inc. is trading at a premium or discount relative to its financial performance.

Aurora Cannabis has shown fluctuating financial performance, with total revenue reaching CAD 94,191,000 in Q3 2026, but net income has been inconsistent, with a net income of CAD 1,820,000 in the same quarter. The gross margin has improved to 47.68% in Q4 2026, showcasing a positive trend in profitability.